Репозиторий
Гомельского государственного медицинского университета
    • русский
    • English
  • English 
    • русский
    • English
  • Login
View Item 
  •   Home page
  • Публикации учёных ГомГМУ в изданиях РБ и за рубежом
  • Публикации в научных журналах
  • 2020
  • View Item
  •   Home page
  • Публикации учёных ГомГМУ в изданиях РБ и за рубежом
  • Публикации в научных журналах
  • 2020
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Advances in anti-cancer immunotherapy: Car-t cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets

View/Open
Зиновкин - копия.pdf (3.170Mb)
Date
2020
Author(s)
Alard, Emilie
Butnariu, Aura-Bianca
Grillo, Marta
Kirkham, Charlotte
Zinovkin, Dmitry Aleksandrovich
Newnham, Louise
Macciochi, Jenna
Metadata
Show full item record
Citation
Advances in anti-cancer immunotherapy: Car-t cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets / E. Alard , A-B.Butnariu , M. Grillo , C. Kirkham , D.A. Zinovkin , L. Newnham, J. Macciochi , M.Z.I. Pranjol // Cancers. - 2020. - Vol. 12(7) 1826.
Abstract
Unlike traditional cancer therapies, such as surgery, radiation and chemotherapy that are typically non-specific, cancer immunotherapy harnesses the high specificity of a patient’s own immune system to selectively kill cancer cells. The immune system is the body’s main cancer surveillance system, but cancers may evade destruction thanks to various immune-suppressing mechanisms. We therefore need to deploy various immunotherapy-based strategies to help bolster the anti-tumour immune responses. These include engineering T cells to express chimeric antigen receptors (CARs) to specifically recognise tumour neoantigens, inactivating immune checkpoints, oncolytic viruses and dendritic cell (DC) vaccines, which have all shown clinical benefit in certain cancers. However, treatment efficacy remains poor due to drug-induced adverse events and immunosuppressive tendencies of the tumour microenvironment. Recent preclinical studies have unveiled novel therapies such as anti-cathepsin antibodies, galectin-1 blockade and anti-OX40 agonistic antibodies, which may be utilised as adjuvant therapies to modulate the tumour microenvironment and permit more ferocious anti-tumour immune response.
Subjects
CAR-T cell
checkpoint inhibitor
dendritic cell vaccines
oncolytic viruses
tumour-induced immune evasion
immunosuppression
drug resistance
galectin-1
cathepsin D
OX40
 
URI
https://elib.gsmu.by/handle/GomSMU/7180
Collections
  • 2020 [62]

Contact Us | Send Feedback
 

 

Browse

All of repositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Contact Us | Send Feedback